Bakish 1993.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM‐III panic disorder with or without agoraphobia Method of diagnosis: Not stated Age: No information provided Sex: No information provided Location: Canada; setting: outpatients Co‐morbidities: Not stated Rescue medication: Chloral hydrate, up to 1 g at night
Interventions	Participants were randomly assigned to either: (1) brofaromine arm (n = 47) Duration: 8 weeks Treatment Protocol: flexible dosage; range = 50 ‐ 150 mg, M and SD not provided (2) clomipramine arm (n = 46) Duration: 8 weeks Treatment Protocol: flexible dosage; range = 25 ‐ 75 mg, M and SD not provided
Outcomes	Time points for assessment: baseline, every two weeks Outcomes: 1. number of panic attacks per week 2. Hamilton Rating Scale for Anxiety (HAMA) 3. Hamilton Rating Scales for Depression (HAM‐D) 4. Clinician Rated Impairment and Disability Scale (CRIDS) 5. Clinician Rated Global Change Scale (CRGCS) 6. Patient Rating Impairment Disability Scale (PRIDS) 7. Patient Rated Anxiety Scale (PRAS) 8. Marks Matthews Phobia Scale 9. Patient Rated Global Change Scale (PRGCS) 10. Daily Panic Inventory (DPI)
Notes	Date of study: Not stated Funding source: Not stated Declarations of interest among the primary researchers: Not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No clear information on incomplete outcome data management.
Selective reporting (reporting bias)	High risk	Data on the scales HAMD, CRIDS, CRGCS, PRIDS, PRAS, PRCGS, DPI not reported at endpoint; data on the scales HAMA and Mark Matthews Phobia Scale are reported only in graphs; number of patients evaluated not specified.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.